Ceralasertib

N/A

Report date: 2026/05/13 20:02:10
NME

Base Information

Drug NameCeralasertib
Drug Alias NameAZD-6738
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerine-protein kinase ATR inhibitors
TargetsSerine-protein kinase ATR
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursMyelodysplastic Syndromes +[34] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[29] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAstrazeneca Plc
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesDana-Farber Cancer InstituteThe AIRC Institute of Molecular OncologyAstrazeneca Pharmaceutical Co Ltd +[11] 
Inactive CompaniesN/A
Active IndicationsMetastatic breast cancerSolid tumoursMyelodysplastic Syndromes +[28] 
Inactive IndicationsSquamous Cell Carcinoma of Head and NeckLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell +[6] 

Other Information

ATC CodeN/A
Related LinksN/A